NAV

NS-398

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
NS-398
DrugBank Accession Number
DB14060
Background

NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 314.357
Monoisotopic: 314.093642386
Chemical Formula
C13H18N2O5S
Synonyms
  • N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide
External IDs
  • NS 398
  • NS-398
  • NS398
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ACyclooxygenase 2
inhibitor
Canis lupus familiaris
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirNS-398 may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Abciximab.
AcebutololNS-398 may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with NS-398.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with NS-398.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9SP55KM2KS
CAS number
123653-11-2
InChI Key
KTDZCOWXCWUPEO-UHFFFAOYSA-N
InChI
InChI=1S/C13H18N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h7-9,11,14H,2-6H2,1H3
IUPAC Name
N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
SMILES
CS(=O)(=O)NC1=CC=C(C=C1OC1CCCCC1)[N+]([O-])=O

References

General References
Not Available
ChemSpider
4393
BindingDB
50029593
ChEBI
73458
ChEMBL
CHEMBL7162
ZINC
ZINC000003791739
PharmGKB
PA166049196
PDBe Ligand
NS4
Wikipedia
NS-398
PDB Entries
3qmo

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0277 mg/mLALOGPS
logP3.04ALOGPS
logP1.93Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)6.81Chemaxon
pKa (Strongest Basic)-4.9Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area98.54 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity76.54 m3·mol-1Chemaxon
Polarizability31.2 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-179.6548342
predicted
DarkChem Lite v0.1.0
[M-H]-166.39767
predicted
DeepCCS 1.0 (2019)
[M+H]+180.1141342
predicted
DarkChem Lite v0.1.0
[M+H]+168.75569
predicted
DeepCCS 1.0 (2019)
[M+Na]+174.84883
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Cyclooxygenase 2
Kind
Protein
Organism
Canis lupus familiaris
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Enzyme binding
Gene Name
PTGS2
Uniprot ID
Q8SPQ9
Uniprot Name
Cyclooxygenase 2
Molecular Weight
68974.625 Da
References
  1. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55-9. [Article]
  2. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer. 2004 Feb 9;90(3):712-9. doi: 10.1038/sj.bjc.6601489. [Article]
  3. Zhang R, Liu Z, Zhang H, Zhang Y, Lin D: The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis. PLoS One. 2016 Jan 13;11(1):e0146808. doi: 10.1371/journal.pone.0146808. eCollection 2016. [Article]
  4. Mastrangelo D, Wisard M, Rohner S, Leisinger H, Iselin CE: Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. [Article]

Enzymes

Details1. Prostaglandin G/H synthase 2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. He W, Pelletier JP, Martel-Pelletier J, Laufer S, Di Battista JA: Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol. 2002 Mar;29(3):546-53. [Article]

Drug created at June 14, 2018 19:37 / Updated at June 17, 2022 22:27